CP 316819

Key Product Details

Product Description

CP 316819 is a selective glycogen phosphorylase inhibitor [IC₅₀ values are 0.017 and 0.034 μM against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent.

Product Specifications for CP 316819

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CP 316819

The following data is based on the product molecular weight 415.87.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.40 mL	12.02 mL	24.05 mL
5 mM	0.48 mL	2.40 mL	4.81 mL
10 mM	0.24 mL	1.20 mL	2.40 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 4 publications citing the usage of this product.

• Freeman Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation site of the enzyme. Br.J.Pharmacol. 2006 PMID: 17016495
• Suh Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-ca J.Pharmacol.Exp.Ther. 2007 PMID: 17251391
• Baker Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 2005 PMID: 16046314

Product Documents for CP 316819